Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sickest cancer patients may get electroporation:

This article was originally published in Clinica

Executive Summary

Genetronics Biomedical has asked the FDA to grant it permission to use its experimental drug delivery technology on patients with aggressive skin, head and neck cancers. The San Diego, California-based company has filed a compassionate use protocol with the agency which would allow it to test its electroporation therapy technique, which uses electric currents to deliver cancer drugs, on patients who have failed standard drug treatment and are not able to, or do not want to, undergo surgery, radiation therapy or additional chemotherapy.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT082133

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel